CN111838674A - Composition with anti-sugar effect and application thereof - Google Patents
Composition with anti-sugar effect and application thereof Download PDFInfo
- Publication number
- CN111838674A CN111838674A CN202010749801.3A CN202010749801A CN111838674A CN 111838674 A CN111838674 A CN 111838674A CN 202010749801 A CN202010749801 A CN 202010749801A CN 111838674 A CN111838674 A CN 111838674A
- Authority
- CN
- China
- Prior art keywords
- extract
- parts
- composition
- anthocyanin
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 230000000694 effects Effects 0.000 title claims abstract description 29
- 239000000284 extract Substances 0.000 claims abstract description 105
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 30
- 240000004153 Hibiscus sabdariffa Species 0.000 claims abstract description 26
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 claims abstract description 26
- 244000235659 Rubus idaeus Species 0.000 claims abstract description 26
- 235000016623 Fragaria vesca Nutrition 0.000 claims abstract description 25
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims abstract description 25
- 241000169546 Lycium ruthenicum Species 0.000 claims abstract description 25
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 25
- 240000000249 Morus alba Species 0.000 claims abstract description 22
- 235000011034 Rubus glaucus Nutrition 0.000 claims abstract description 18
- 235000009122 Rubus idaeus Nutrition 0.000 claims abstract description 18
- 235000011511 Diospyros Nutrition 0.000 claims abstract description 15
- 244000236655 Diospyros kaki Species 0.000 claims abstract description 15
- 229920001864 tannin Polymers 0.000 claims abstract description 13
- 235000018553 tannin Nutrition 0.000 claims abstract description 13
- 239000001648 tannin Substances 0.000 claims abstract description 13
- 238000005336 cracking Methods 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 229920001202 Inulin Polymers 0.000 claims abstract description 4
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 4
- 229940029339 inulin Drugs 0.000 claims abstract description 4
- 238000000899 pressurised-fluid extraction Methods 0.000 claims abstract description 3
- 240000009088 Fragaria x ananassa Species 0.000 claims abstract 5
- 229930002877 anthocyanin Natural products 0.000 claims description 65
- 235000010208 anthocyanin Nutrition 0.000 claims description 65
- 239000004410 anthocyanin Substances 0.000 claims description 65
- 150000004636 anthocyanins Chemical class 0.000 claims description 65
- 239000007788 liquid Substances 0.000 claims description 29
- 239000000287 crude extract Substances 0.000 claims description 17
- 235000015810 grayleaf red raspberry Nutrition 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 claims description 5
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 claims description 4
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 claims description 4
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 238000006116 polymerization reaction Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 claims description 4
- 229920002414 procyanidin Polymers 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 241000218231 Moraceae Species 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical class O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 2
- IWTWNQZWPPSSQB-RUYQGPSPSA-O Petunidin 3-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](Oc2c(-c3cc(OC)c(O)c(O)c3)[o+]c3c(c(O)cc(O)c3)c2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O1 IWTWNQZWPPSSQB-RUYQGPSPSA-O 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- IWTWNQZWPPSSQB-MTUZZJJTSA-O petunidin 3-rutinoside Chemical compound OC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)O2)O)=C1 IWTWNQZWPPSSQB-MTUZZJJTSA-O 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 235000021012 strawberries Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000004185 countercurrent chromatography Methods 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 10
- 235000013305 food Nutrition 0.000 abstract description 8
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000002537 cosmetic Substances 0.000 abstract description 2
- 230000007760 free radical scavenging Effects 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 23
- 241000220223 Fragaria Species 0.000 description 22
- 239000000243 solution Substances 0.000 description 13
- 238000001514 detection method Methods 0.000 description 12
- 230000006872 improvement Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 239000007791 liquid phase Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000010828 elution Methods 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000009210 therapy by ultrasound Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000011514 Familial renal glucosuria Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- YTMNONATNXDQJF-UBNZBFALSA-N chrysanthemin Chemical compound [Cl-].O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C(O)=C1 YTMNONATNXDQJF-UBNZBFALSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 238000010587 phase diagram Methods 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000007278 renal glycosuria Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a composition with an anti-sugar effect and application thereof, wherein the composition comprises the following raw materials in parts by weight: 5-10 parts of mulberry extract, 5-10 parts of raspberry extract, 15-20 parts of strawberry extract, 5-10 parts of roselle extract, 15-20 parts of lycium ruthenicum extract, 5-10 parts of persimmon tannin cracking product, 35-50 parts of oligomeric inulin and 1-5 parts of citric acid; the composition is used for preparing medicines or health-care foods for treating, delaying or relieving ACEs related diseases; the composition can obviously inhibit the formation of AGEs, simultaneously shows extremely strong free radical scavenging capacity, can be gradually popularized to the fields of cosmetics, foods and medicines, and has wide future prospect.
Description
Technical Field
The invention relates to the technical field of health-care food, in particular to a composition with an anti-sugar effect and application thereof.
Background
Advanced glycation end products (AGEs) can be divided into endogenous AGEs and exogenous AGEs. Endogenous AGEs are produced by reaction of proteins in organisms and redundant saccharides, and particularly have the highest content in blood and cells of patients with renal failure and diabetes, so that physiological changes such as diabetes, renal failure and the like are influenced, and human health is seriously influenced. Exogenous AGEs refer to AGEs taken in by organisms from the outside, mostly carried in by food, also called food-borne AGEs.
As the AGEs can change the structure and the function of protein, the accumulation of the AGEs has great relation with diseases such as neuropathy, Alzheimer syndrome, atherosclerosis and the like and can cause diabetic complications such as diabetic nephropathy, retinopathy and the like, and in addition, the AGEs can be combined with a specific receptor of a cell membrane and cause the pathological changes of tissues and organs by abnormally activating a signal path such as NF-kappa B, MAPK and the like. At present, AGEs inhibitors such as aspirin and aminoguanidine used in medical clinic all have certain toxic and side effects. Therefore, there is a need to develop novel AGEs inhibitors that are free of adverse effects.
Disclosure of Invention
In view of the problems of the prior art, the invention aims to provide a composition with anti-saccharification effect and application thereof.
In order to achieve the purpose, the invention provides the following scheme:
the invention provides a composition with an anti-sugar effect, which comprises the following raw materials in parts by weight: 5-10 parts of mulberry extract, 5-10 parts of raspberry extract, 15-20 parts of strawberry extract, 5-10 parts of roselle extract, 15-20 parts of lycium ruthenicum extract, 5-10 parts of persimmon tannin cracking product, 35-50 parts of oligomeric inulin and 1-5 parts of citric acid. The main component of the fruit extract is anthocyanin which is extremely unstable in aqueous solution, so in order to improve the stability of the anthocyanin and increase the activity of the anthocyanin for inhibiting AGEs, the invention adds oligomer procyanidin as a stabilizer and a synergist of the anthocyanin.
As a further improvement of the invention, the content of Cy-3-glc and Cy-3-rut2 main anthocyanins in the mulberry extract is not less than 47.5% and 20.5%; the content of Cy-3-soph and Cy-3-glc 2 major anthocyanins in the red raspberry extract is not less than 30% and 37.5%; the Pg-3-glc content in the strawberry extract is not less than 60%; the content of 3 kinds of anthocyanin Dp-3-sam, Dp-3-glc and Cy-3-glc in the Hibiscus sabdariffa extract is not less than 8.5%, 14.5% and 10%; the content of petunidin-3-rutinoside in the Lycium ruthenicum Murr extract is not less than 60%.
As a further improvement of the invention, the persimmon tannin cracking product is persimmon procyanidin oligomer obtained by carrying out high-pressure catalytic hydrogenolysis on persimmon tannin, the average polymerization degree is not more than 3, and the content of A-ECG and EGCG dimer is not less than 10%.
As a further improvement of the invention, the polymerization degree of the oligoinulin is not more than 10.
As a further improvement of the invention, the preparation methods of the mulberry extract, the raspberry extract, the strawberry extract, the roselle extract and the lycium ruthenicum extract are as follows: respectively weighing and grinding the mulberries, the red raspberries, the strawberries, the roselle and the lycium ruthenicum mill, extracting by adopting hydrochloric acid methanol, enriching by AB-8 macroporous resin, eluting, and preparing by medium pressure chromatography to obtain a crude extract rich in anthocyanin.
The mulberry extract, the raspberry extract, the strawberry extract, the roselle extract and the lycium ruthenicum extract are mainly anthocyanin crude extracts, and the specific preparation method comprises the following steps: weighing Mori fructus, Rubi fructus, strawberry, calyx Hibisci Sabdariffae and fructus Lycii respectively, grinding, adding 0.1% hydrochloric acid-containing methanol at a ratio of material to liquid (m/m) of 1:2, placing in dark place, performing ultrasound treatment at 40 deg.C for 30min, filtering the extractive solution with gauze, performing ultrasound treatment on the filter residue under the same conditions for 3 times, mixing the extractive solutions, and removing methanol with rotary evaporator under vacuum condition at 45 deg.C. Filtering the anthocyanin concentrated solution with Buchner funnel, adjusting pH to 1.5, loading into chromatographic column filled with AB-8 resin material, adsorbing for 60min, removing impurities such as protein and sugar with 0.1% volume fraction hydrochloric acid distilled water, detecting eluate with phenol-sulfuric acid method to colorless, eluting anthocyanin with 60% ethanol with pH of 2.5, collecting eluate, and removing ethanol by rotary evaporation at 45 deg.C under vacuum condition. Extracting the concentrated solution with ethyl acetate at a ratio of 1:1(v/v), repeatedly extracting for 3 times under the same conditions, combining water phases, vacuum concentrating, freeze-drying, and further purifying by medium-pressure preparative chromatography to obtain crude anthocyanin extract.
The invention also provides application of the composition with the anti-sugar effect in preparing medicines or health-care foods for treating, delaying or relieving ACEs related diseases.
As a further improvement of the invention, the AGEs-related diseases are diabetes, atherosclerosis, chronic kidney disease, liver disease or neurodegenerative disease.
As a further improvement of the invention, the medicine also comprises pharmaceutically acceptable auxiliary materials, and the health food also comprises the auxiliary materials which are acceptable in food science.
As a further improvement of the invention, the medicament is in the form of oral preparation or injection preparation.
As a further improvement of the invention, the oral preparation is tablets, powder, capsules, granules, pills, powder, paste or oral liquid.
The invention discloses the following technical effects:
the invention provides a composition with the anti-sugar effect, which takes a plurality of fruit extracts rich in anthocyanin as raw materials, fully utilizes the synergistic effect of the anthocyanin and the oligomer, and adds oligoinulin which can improve the taste and has stable anthocyanin and procyanidin and citric acid which can improve the taste on the basis of the synergistic effect of the anthocyanin and the oligomer. The composition with the anti-sugar effect can obviously inhibit the formation of AGEs and simultaneously shows extremely strong free radical scavenging capacity. In summary, all experiments demonstrated that the composition had a significant effect of inhibiting the formation of AGEs. The raw materials related by the invention are all food raw materials, have small side effect and high safety, can be applied to human bodies, can be gradually popularized to the fields of cosmetics, foods and medicines, and have wide future prospects.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings needed to be used in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings without inventive exercise.
FIG. 1 is a high performance liquid chromatogram of anthocyanin content in a mulberry extract, wherein A is a high performance liquid chromatogram of the mulberry extract at a wavelength of 280nm, and B is a high performance liquid chromatogram of the mulberry extract at a wavelength of 520 nm;
FIG. 2 is a high performance liquid chromatogram of anthocyanin content in a raspberry extract, wherein A is a high performance liquid chromatogram of a raspberry extract at a wavelength of 280nm, and B is a high performance liquid chromatogram of a raspberry extract at a wavelength of 520 nm;
FIG. 3 is a high performance liquid chromatogram of the anthocyanin content of a strawberry extract, wherein A is the high performance liquid chromatogram of the strawberry extract at a wavelength of 280nm, and B is the high performance liquid chromatogram of the strawberry extract at a wavelength of 520 nm;
FIG. 4 is a high performance liquid chromatogram of the anthocyanin content of Hibiscus sabdariffa extract, wherein A is the high performance liquid chromatogram of the Hibiscus sabdariffa extract at a wavelength of 280nm, and B is the high performance liquid chromatogram of the Hibiscus sabdariffa extract at a wavelength of 520 nm;
FIG. 5 is a high performance liquid chromatogram of the anthocyanin content of Lycium ruthenicum Murr extract, wherein A is a high performance liquid chromatogram of Lycium ruthenicum Murr extract at a wavelength of 280nm, and B is a high performance liquid chromatogram of Lycium ruthenicum Murr extract at a wavelength of 520 nm;
FIG. 6 is a graph of the amelioration of high AGEs feed toxicity by a preferred composition of the present invention, wherein A is a graph of the significant inhibition of the activation of the RAGE-p38MAPK-NF- κ B signaling pathway by the preferred composition of the present invention, and B is a graph of the significant inhibition of the expression of TNF- α and IL-6 inflammatory factors in the liver by the preferred composition of the present invention.
Detailed Description
Reference will now be made in detail to various exemplary embodiments of the invention, the detailed description should not be construed as limiting the invention but as a more detailed description of certain aspects, features and embodiments of the invention.
It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. Further, for numerical ranges in this disclosure, it is understood that each intervening value, between the upper and lower limit of that range, is also specifically disclosed. Every smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in a stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference herein for the purpose of disclosing and describing the methods and/or materials associated with the documents. In case of conflict with any incorporated document, the present specification will control.
It will be apparent to those skilled in the art that various modifications and variations can be made in the specific embodiments of the present disclosure without departing from the scope or spirit of the disclosure. Other embodiments will be apparent to those skilled in the art from consideration of the specification. The specification and examples are exemplary only.
As used herein, the terms "comprising," "including," "having," "containing," and the like are open-ended terms that mean including, but not limited to.
EXAMPLE 1 preparation of crude anthocyanin extract
Respectively taking 50g of mulberry, raspberry, strawberry, roselle and lycium ruthenicum, grinding, adding 100ml of methanol containing 0.1% hydrochloric acid at a material-liquid ratio (m/m) of 1:2, placing in a dark place, carrying out ultrasonic treatment at 40 ℃ for 30min, filtering the extracting solution with gauze, repeatedly carrying out ultrasonic treatment on filter residues for 3 times under the same condition, combining the extracting solutions, and removing the methanol by using a rotary evaporator under the vacuum condition of 45 ℃. Filtering the anthocyanin concentrated solution with Buchner funnel, adjusting pH to 1.5, loading into chromatographic column filled with AB-8 resin material, adsorbing for 60min, removing impurities such as protein and sugar with 0.1% volume fraction hydrochloric acid distilled water, detecting eluate with phenol-sulfuric acid method to colorless, eluting anthocyanin with 60% ethanol with pH of 2.5, collecting eluate, and removing ethanol by rotary evaporation at 45 deg.C under vacuum condition. Extracting the concentrated solution with ethyl acetate at a ratio of 1:1(v/v), repeating the extraction for 3 times under the same conditions, combining the water phases, vacuum concentrating, and freeze drying to obtain 5 kinds of crude anthocyanin extracts.
HPLC detection analysis of 5 kinds of anthocyanin crude extracts
1mg of Cy-3-glc standard substance is quantitatively weighed and dissolved in HCl methanol solution with volume fraction of 0.1% to prepare 1mg/ml Cy-3-glc standard solution, and then the standard solution is filtered by a 0.45 mu m filter membrane into a brown liquid phase bottle for liquid phase analysis. The liquid chromatography conditions were as follows: a Waters C18 column (250 mm. times.4.6 mm,5 μm) was used; mobile phase A: 5% formic acid water, mobile phase B: methanol; gradient elution conditions: 0-10 min, 5% -20% of B; 10min to 15min, 20 percent to 20 percent of B; 15 min-30 min, 20% -25% B; 30-35 min, 25-25% B; 35-40 min, 25-33% B; 40 min-42 min, 33% -5% B; 42min to 47min, 5 percent to 5 percent of B; the flow rate is 1mL/min, the detection wavelength is 520nm by a PDA detector, the sample introduction amount of the standard substance is 1, 2, 4, 8 and 16 mu L, the sample introduction is repeated for 3 times in each volume, and the average peak area of each sample introduction volume is calculated. The mass (. mu.g) was plotted on the abscissa and the peak area on the ordinate, giving a standard curve of y 2000000x-42033 (R)2=0.9999)。
Detection of anthocyanin content in 5 kinds of anthocyanin crude extracts
Respectively taking 5 anthocyanin crude extracts, quantitatively dissolving with HCl methanol containing 0.1% of volume fraction, taking a proper amount of dissolving solution, filtering with a filter membrane of 0.45 mu m, transferring into a brown liquid phase bottle, and analyzing the liquid phase conditions in the same HPLC detection of the 5 anthocyanin crude extracts, wherein the detection wavelengths are 280nm and 520 nm. And substituting the obtained peak area into the standard curve for quantitative calculation.
Separating 5 kinds of anthocyanin crude extract with MPPSS
300mg of 5 kinds of crude extracts of anthocyanin are respectively taken and ultrasonically dissolved by 2mL of analytically pure methanol and filtered by a filter membrane with the diameter of 0.45 mu m for standby. The gradient elution conditions of the crude extracts of the anthocyanin of the mulberries and the red raspberries are as follows: 0-2 min, 20% B; 2-22 min, 20% -30% of B; 22-32 min, 30-40% of B, and the gradient elution conditions of the crude extracts of strawberry and roselle anthocyanin are as follows: 0-2 min, 20% B; 2-22 min, 20-30% of B, 22-32 min, 30-40% of B, 32-47 min and 40-45% of B, wherein the elution conditions of the lycium ruthenicum anthocyanin crude extract are as follows: 0-2 min, 20% B; 2-22 min, 20% -30% of B; 22-32 min, 30% -40% B; 32-47 min, 40-45% B; 47-57 min, 45-60% of B, a detection wavelength of 280nm, a preparation column model Flash C18(80g, 20-35 μm, 100A), 2 columns connected in series, and a sample is subjected to peak cutting and collection, wherein the collection unit is 10 mL.
In the MPSS separation process, research shows that anthocyanin is stable under an acidic condition, tailing conditions can be effectively reduced and the separation effect can be well improved by adding formic acid, the flow rate is 40mL/min, the A mobile phase is 2% formic acid water, and the B mobile phase is methanol.
Determining content of main anthocyanin in the crude extract
Respectively mixing freeze-dried samples of different anthocyanin components obtained by MPSSs separation according to the same proportion, dissolving a certain amount of the freeze-dried samples by using 0.1% HCl methanol, filtering the mixture by using a 0.45 mu m filter membrane, performing liquid phase analysis, performing HPLC detection analysis on 5 kinds of anthocyanin crude extracts under the same liquid phase condition, injecting 10 mu L of the sample, and detecting the wavelengths of 280nm and 520 nm.
Structural identification of the obtained anthocyanin fraction by UPLC-MS
Chromatographic columnBEH Waters C18(2.1 mm. times.100 mm,1.7 μm); the sample volume is 2 mu L; the column temperature is 45 ℃; the flow rate is 0.4 mL/min; mobile phase A: 0.1% formic acid water, mobile phase B: methanol; elution conditions: 0-0.5 min, 2% -2% B; 0.5-1 min, 2% -5% of B; 1-2 min, 5% -10% of B; 2-5 min, 10% -20% of B; 5-8 min, 20% -100% B; 8-11 min, 100% B; 11-11.5 min, 100% -5% B; 11.5-13 min, 5% -5% B. Electrospray ionization ion source, scanning particle range: 50-1000 m/z, positive ion mode, atomizer pressure of 40psi, gas flow rate of 10L/min, dryer temperature of 350 ℃, capillary voltage of 3500V.
The detection result of the high performance liquid chromatography of anthocyanin content in the mulberry extract is shown in figure 1, wherein A is the high performance liquid chromatogram of the mulberry extract at the wavelength of 280nm, and B is the high performance liquid chromatogram of the mulberry extract at the wavelength of 520 nm. As can be seen from fig. 1A and 1B, there are 2 main peaks and fewer peaks at both wavelengths, and the content of 2 main anthocyanins in mulberry was calculated to be 47.5% and 20.5% by using cyanidin-3-glucoside (Cy-3-glc) as a standard.
The high performance liquid chromatography detection result of anthocyanin content in the red raspberry extract is shown in fig. 2, wherein A is the high performance liquid chromatogram of the red raspberry extract at the wavelength of 280nm, and B is the high performance liquid chromatogram of the red raspberry extract at the wavelength of 520 nm. As can be seen from FIG. 2, the crude extract of raspberry anthocyanin has 2 main peaks at 520nm, and many impurity peaks before the 2 major peaks of anthocyanin at 280 nm. Taking Cy-3-glc as a standard substance, calculating the contents of 2 main anthocyanins in the crude extract of raspberry anthocyanin to be 30% and 37.5% respectively.
The detection result of the strawberry extract anthocyanin content by high performance liquid chromatography is shown in figure 3, wherein A is a high performance liquid chromatogram of the strawberry extract at a wavelength of 280nm, and B is a high performance liquid chromatogram of the strawberry extract at a wavelength of 520 nm. As can be seen from FIG. 3, there are 1 major peak at 520nm wavelength, indicating that the strawberry flower extract mainly contains 1 anthocyanin, while at 280nm wavelength, there are more impurities before and after the major anthocyanin peak, and the content of 1 major anthocyanin in the strawberry anthocyanin crude extract is 60% using Cy-3-glc as the standard.
The high performance liquid chromatography detection result of anthocyanin content in Hibiscus sabdariffa extract is shown in figure 4, wherein A is high performance liquid chromatogram of Hibiscus sabdariffa extract at wavelength of 280nm, and B is high performance liquid chromatogram of Hibiscus sabdariffa extract at wavelength of 520 nm. As can be seen from FIG. 4, the crude Hibiscus sabdariffa anthocyanin contains 3 major anthocyanins at 520nm, and contains some impurities before the major peaks of 3 anthocyanins at 280nm, and the content of 3 anthocyanins in Hibiscus sabdariffa is calculated to be 8.5%, 14.5% and 10% respectively, using Cy-3-glc as standard.
The high performance liquid chromatography detection result of anthocyanin content in Lycium ruthenicum Murr extract is shown in FIG. 5, wherein A is a high performance liquid chromatogram of Lycium ruthenicum Murr extract at a wavelength of 280nm, and B is a high performance liquid chromatogram of Lycium ruthenicum Murr extract at a wavelength of 520 nm. As can be seen from FIG. 5, there are only 1 main peak at 520nm wavelength, and 280nm liquid phase diagram shows that many non-anthocyanin substances are present before the main peak of anthocyanin, and the content of 1 main anthocyanin contained in Lycium ruthenicum is calculated to be 60% by taking Cy-3-glc as a standard.
Example 2
The composition with the anti-sugar effect comprises the following raw materials in parts by weight: 5 parts of mulberry extract, 8 parts of raspberry extract, 15 parts of strawberry extract, 6 parts of roselle extract, 15 parts of lycium ruthenicum extract, 10 parts of persimmon tannin cracking product, 35 parts of oligomeric inulin and 1 part of citric acid. Mixing according to weight ratio.
Example 3
The composition with the anti-sugar effect comprises the following raw materials in parts by weight: 10 parts of mulberry extract, 5 parts of raspberry extract, 18 parts of strawberry extract, 8 parts of roselle extract, 18 parts of lycium ruthenicum extract, 6 parts of persimmon tannin cracking product, 40 parts of oligoinulin and 3 parts of citric acid. Mixing according to weight ratio.
Example 4
The composition with the anti-sugar effect comprises the following raw materials in parts by weight: 8 parts of mulberry extract, 6 parts of raspberry extract, 19 parts of strawberry extract, 5 parts of roselle extract, 16 parts of lycium ruthenicum extract, 7 parts of persimmon tannin cracking product, 45 parts of oligoinulin and 4 parts of citric acid. Mixing according to weight ratio.
Example 5
The composition with the anti-sugar effect comprises the following raw materials in parts by weight: 9 parts of mulberry extract, 9 parts of raspberry extract, 20 parts of strawberry extract, 10 parts of roselle extract, 15 parts of lycium ruthenicum extract, 5 parts of persimmon tannin cracking product, 50 parts of oligoinulin and 5 parts of citric acid. Mixing according to weight ratio.
Example 6
The composition with the anti-sugar effect comprises the following raw materials in parts by weight: 10 parts of mulberry extract, 10 parts of raspberry extract, 18 parts of strawberry extract, 8 parts of roselle extract, 20 parts of lycium ruthenicum extract, 7 parts of persimmon tannin cracking product, 48 parts of oligoinulin and 3 parts of citric acid. Mixing according to weight ratio.
Evaluation of anti-glycation Effect
The inhibition of AGEs formation by the compositions of examples 2-6 was evaluated using a glucose- β -Lg mimetic system. According to the fluorescence of AGEs, an F-4600 fluorescence spectrometer is adopted to determine the fluorescence intensity of fluorescent AGEs after a blank control group and a composition test group are added for reaction for 7d under the conditions of an excitation wavelength of 325nm and an emission wavelength of 440nm, and the inhibition rate of the composition to the fluorescent AGEs is calculated, wherein the calculation method comprises the following steps:
wherein, F0-fluorescence intensity of blank control group; f1-fluorescence intensity of test group
The results show that the optimal composition (the composition indicated in example 2) of the present invention has a significant function of inhibiting the production of glycosylation products, and the IC thereof50At 378. mu.g/ml, IC of examples 3, 4, 5, 650475. mu.g/ml, 492. mu.g/ml, 486. mu.g/ml and 428. mu.g/ml, respectively.
Mouse experiments to evaluate the anti-glycation of the compositions of the invention
SPF rats are divided into three groups and fed with normal feed, high-dose AGEs feed and feed (0.5 percent, w/w) containing a composition (the composition in example 2: 5 parts of mulberry extract, 8 parts of raspberry extract, 15 parts of strawberry extract, 6 parts of roselle extract, 15 parts of Lycium ruthenicum extract, 10 parts of persimmon tannin cleavage product, 35 parts of oligoinulin and 1 part of citric acid) respectively, and the expression of RAGE, p38MAPK and NF-kappa B in the liver of the rats is detected by immunohistochemical staining, and the result is shown in figure 6, and shows that the composition can obviously inhibit the activation of a RAGE-p38 MAPK-NF-kappa B signal channel. The expression of the inflammatory factors TNF-alpha (24%) and IL-6 (50%) in the liver is detected by an ELISA method, and the result shows that the composition provided by the invention can obviously reduce the expression of the inflammatory factors. These results indicate that the compositions of the present invention have a significant in vivo anti-glycation effect.
The above-described embodiments are merely illustrative of the preferred embodiments of the present invention, and do not limit the scope of the present invention, and various modifications and improvements of the technical solutions of the present invention can be made by those skilled in the art without departing from the spirit of the present invention, and the technical solutions of the present invention are within the scope of the present invention defined by the claims.
Claims (10)
1. The composition with the anti-sugar effect is characterized by comprising the following components in parts by weight: 5-10 parts of mulberry extract, 5-10 parts of raspberry extract, 15-20 parts of strawberry extract, 5-10 parts of roselle extract, 15-20 parts of lycium ruthenicum extract, 5-10 parts of persimmon tannin cracking product, 35-50 parts of oligomeric inulin and 1-5 parts of citric acid.
2. The composition with the anti-sugar effect according to claim 1, wherein the content of Cy-3-glc and Cy-3-rut2 major anthocyanins in the mulberry extract is not less than 47.5% and 20.5%; the content of Cy-3-soph and Cy-3-glc 2 major anthocyanins in the red raspberry extract is not less than 30% and 37.5%; the Pg-3-glc content in the strawberry extract is not less than 60%; the content of 3 kinds of anthocyanin Dp-3-sam, Dp-3-glc and Cy-3-glc in the Hibiscus sabdariffa extract is not less than 8.5%, 14.5% and 10%; the content of petunidin-3-rutinoside in the Lycium ruthenicum Murr extract is not less than 60%.
3. The composition with anti-sugar effect as claimed in claim 1, wherein the persimmon tannin cracking product is persimmon procyanidin oligomer obtained by subjecting persimmon tannin to high pressure catalytic hydrogenolysis, the average degree of polymerization is not more than 3, and the content of A-ECG and EGCG dimer is not less than 10%.
4. The composition having an anti-sugar effect according to claim 1, wherein the polymerization degree of oligoinulin is not more than 10.
5. The composition with the sugar-resistant effect according to claim 1, wherein the mulberry extract, the raspberry extract, the strawberry extract, the roselle extract and the lycium ruthenicum extract are prepared by the following steps: weighing and grinding mulberries, red raspberries, strawberries, roselle and lycium ruthenicum mill respectively, extracting by adopting hydrochloric acid methanol, enriching by AB-8 macroporous resin, enriching by medium-pressure countercurrent chromatography, and eluting to obtain a crude extract rich in anthocyanin.
6. Use of the composition with anti-sugar effect according to any one of claims 1 to 5 in the preparation of a medicament or health food for treating, delaying or alleviating ACEs-related diseases.
7. The use according to claim 6, wherein the AGEs-related diseases are diabetes, atherosclerosis, chronic kidney disease, liver disease or neurodegenerative disease.
8. The use according to claim 6, wherein the medicament further comprises pharmaceutically acceptable excipients and the health food further comprises dietetically acceptable excipients.
9. The use according to claim 8, wherein the medicament is in the form of an oral formulation or an injectable formulation.
10. The use according to claim 9, wherein the oral formulation is a tablet, powder, capsule, granule, pill, powder, paste, or oral liquid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010749801.3A CN111838674A (en) | 2020-07-30 | 2020-07-30 | Composition with anti-sugar effect and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010749801.3A CN111838674A (en) | 2020-07-30 | 2020-07-30 | Composition with anti-sugar effect and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111838674A true CN111838674A (en) | 2020-10-30 |
Family
ID=72945972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010749801.3A Pending CN111838674A (en) | 2020-07-30 | 2020-07-30 | Composition with anti-sugar effect and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111838674A (en) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070060533A1 (en) * | 2003-10-24 | 2007-03-15 | Meiji Seika Kaisha Ltd. | Novel inhibitor of the formation of advanced glycation end product and aldose reductase inhibitor |
CN102718817A (en) * | 2011-03-31 | 2012-10-10 | 成都华高药业有限公司 | Method for preparing anthocyanin extract from black bean peel |
CN105410546A (en) * | 2015-11-27 | 2016-03-23 | 魏海青 | Anthocyanin-rich composite plant beverage and preparation method thereof |
JP2017141201A (en) * | 2016-02-12 | 2017-08-17 | 株式会社東洋新薬 | Glycosylation inhibitor |
CN108409703A (en) * | 2018-06-07 | 2018-08-17 | 中国农业大学 | A kind of method of anthocyanin of the Simulation moving bed separation with delaying senility function |
CN109090611A (en) * | 2018-10-26 | 2018-12-28 | 汤臣倍健股份有限公司 | A kind of AGEs composite inhibiting and its application, preparation method, preparation |
CN109938350A (en) * | 2019-04-10 | 2019-06-28 | 浙江省农业科学院 | A kind of myrica ruba marc alcohol extract and preparation method with effect of lowering blood sugar |
CN110574927A (en) * | 2019-08-30 | 2019-12-17 | 北京姿美堂生物技术有限公司 | Anti-saccharification composition and preparation method thereof |
CN110664868A (en) * | 2019-10-15 | 2020-01-10 | 无限极(中国)有限公司 | Composition with anti-glycosylation effect and application thereof |
CN111205259A (en) * | 2020-01-08 | 2020-05-29 | 华中农业大学 | Preparation method and application of persimmon oligomeric proanthocyanidins |
-
2020
- 2020-07-30 CN CN202010749801.3A patent/CN111838674A/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070060533A1 (en) * | 2003-10-24 | 2007-03-15 | Meiji Seika Kaisha Ltd. | Novel inhibitor of the formation of advanced glycation end product and aldose reductase inhibitor |
CN102718817A (en) * | 2011-03-31 | 2012-10-10 | 成都华高药业有限公司 | Method for preparing anthocyanin extract from black bean peel |
CN105410546A (en) * | 2015-11-27 | 2016-03-23 | 魏海青 | Anthocyanin-rich composite plant beverage and preparation method thereof |
JP2017141201A (en) * | 2016-02-12 | 2017-08-17 | 株式会社東洋新薬 | Glycosylation inhibitor |
CN108409703A (en) * | 2018-06-07 | 2018-08-17 | 中国农业大学 | A kind of method of anthocyanin of the Simulation moving bed separation with delaying senility function |
CN109090611A (en) * | 2018-10-26 | 2018-12-28 | 汤臣倍健股份有限公司 | A kind of AGEs composite inhibiting and its application, preparation method, preparation |
CN109938350A (en) * | 2019-04-10 | 2019-06-28 | 浙江省农业科学院 | A kind of myrica ruba marc alcohol extract and preparation method with effect of lowering blood sugar |
CN110574927A (en) * | 2019-08-30 | 2019-12-17 | 北京姿美堂生物技术有限公司 | Anti-saccharification composition and preparation method thereof |
CN110664868A (en) * | 2019-10-15 | 2020-01-10 | 无限极(中国)有限公司 | Composition with anti-glycosylation effect and application thereof |
CN111205259A (en) * | 2020-01-08 | 2020-05-29 | 华中农业大学 | Preparation method and application of persimmon oligomeric proanthocyanidins |
Non-Patent Citations (4)
Title |
---|
刘莉: "《蔬菜营养学》", 30 June 2014, 天津大学出版社 * |
张朝红 等: "桑椹花色苷对晚期糖基化末端产物抑制作用及其机制分析", 《现代食品科技》 * |
杜霞 等: "中压快速分离系统大量制备高纯度桑葚和树莓花色苷的工艺研究", 《食品工业科技》 * |
贾东升 等: "黑枸杞花色苷对酒精性肝损伤的保护作用", 《食品研究与开发》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9770479B2 (en) | Extract of Rehmannia glutinasa Libosch for reducing blood sugar, reducing blood fat, treating leukemia, and preparation method and uses thereof | |
CN102600219B (en) | Total flavone extract of abelmoschus manihot and preparing method of total flavone extract | |
CA2559826C (en) | Traditional chinese medicine preparation for cardio-cerebral blood vessel diseases and its preparing method | |
Zhou et al. | Separation and purification of α-glucosidase inhibitors from Polygonatum odoratum by stepwise high-speed counter-current chromatography combined with Sephadex LH-20 chromatography target-guided by ultrafiltration–HPLC screening | |
CN101985644B (en) | Momordica charantia polypeptide, preparation method and application thereof | |
KR20060069349A (en) | Method for preparing a centella asiatica extract rich in madecassoside and in terminoloside | |
CN103110651A (en) | Application of active ingredient namely loganin in dogwood in preparation of medicaments for treating diabetes | |
CN111018933A (en) | Fructus momordicae extract product and preparation method and application thereof | |
CN103006878B (en) | A kind of fresh rehmannia root total glycosides extractive and preparation method and application | |
CN105859803B (en) | A kind of preparation method of galloyl glucose | |
CN102134268B (en) | Method for preparing panax japonicus saponin IVa and application of panax japonicus saponin IVa in preparing a medicament for protecting liver and lowering transaminase | |
CN107349244B (en) | Extraction method of malonyl ginsenoside | |
CN113499353A (en) | Preparation method and application of ginseng and pilose antler refined component with anti-Alzheimer disease activity | |
CN113577239A (en) | American ginseng glycopeptide and preparation method and application thereof | |
CN110680802B (en) | Tetrandrine injection and preparation method thereof | |
CN112159451A (en) | Gynostemma pentaphylla saponin extract and preparation method thereof | |
CN115433248B (en) | Novel amino acid derivative separation and identification in red ginseng and novel application thereof | |
CN111838674A (en) | Composition with anti-sugar effect and application thereof | |
CN101422529B (en) | Preparation method of traditional Chinese medicine preparation | |
CN103381200A (en) | White mulberry root-bark total alkaloid extract and preparation and application thereof | |
CN113185618B (en) | Anti-alcoholic liver injury rhizoma atractylodis macrocephalae polysaccharide and preparation method and application thereof | |
CA2455655C (en) | A glycoprotein with antidiabetic, antihypertensive, antiobesity and antihyperlipidemic effects from grifola frondosa, and a method for preparing same | |
KR100839185B1 (en) | Composition comprising plantamajoside for treating or preventing diabete and diabetic complication | |
CN113670680A (en) | Preparation method of acarbose impurity reference substance | |
CN107513092B (en) | Malonyl ginsenoside Rb1Preparation method and medical application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201030 |